Blood Res.  2016 Jun;51(2):137-138. 10.5045/br.2016.51.2.137.

Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab

• Tendas A
• Niscola P
• Scaramucci L
• Cupelli L
• Perrotti A
• de Fabritiis P

• KMID: 2309217
• DOI: http://doi.org/10.5045/br.2016.51.2.137

Abstract

No abstract available.

MeSH Terms

Red-Cell Aplasia, Pure*
Rituximab*
Rituximab

Figure

• 

  Fig. 1 Treatments and their effects on the patient's hemoglobin (Hb) level and reticulocyte count.Abbreviations: CyA, oral cyclosporine A (mg/day); RTX, rituximab; PDN 1, oral prednisone 1 mg/m2/day; AZT, oral azathioprine.

Reference

1. Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol. 2008; 142:505–514. PMID: 18510682.

2. D'Arena G, Vigliotti ML, Dell'Olio M, et al. Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia. Eur J Haematol. 2009; 82:235–239. PMID: 19067738.

3. Scaramucci L, Niscola P, Ales M, et al. Pure red cell aplasia associated with hemolytic anemia refractory to standard measures and resolved by rituximab in an elderly patient. Int J Hematol. 2008; 88:343–344. PMID: 18807120.

4. Gupta RK, Ezeonyeji AN, Thomas AS, Scully MA, Ehrenstein MR, Isenberg DA. A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: response to rituximab and cyclophosphamide. Lupus. 2011; 20:1547–1550. PMID: 21993386.

5. Jung SH, Ahn JS, Yang DH, et al. Successful treatment of pure red cell aplasia with rituximab in patients after abo-compatible allogeneic hematopoietic stem cell transplantation. Case Rep Oncol. 2012; 5:110–113. PMID: 22539923.